Abstract:6000 Background: The benefit of concurrent chemotherapy to treat intermediate-risk (stage II and T3N0M0) nasopharyngeal carcinoma (NPC) remains controversial. We aimed to assess whether concurrent chemotherapy can be omitted safely for intermediate-risk NPC patients treated with intensity-modulated radiotherapy. Methods: This multi-centre, noninferiority, open-label, randomised controlled, phase III trial was done at 4 hospitals in China. Patients aged 18–65 years, with histologically confirmed, stage T1-2N1/T2-3N0M0, a Karnofsky score of at least 70 were randomly assigned (1:1) to receive either concurrent chemoradiotherapy (CCRT) (cisplatin 100 mg/m² on days 1, 22, and 43) or radiotherapy alone (RT). Key exclusion criteria included: maximal axial diameter of neck lymph node ≥30mm, positive neck lymph node at level IV or lower, pretherapy plasma EBV DNA level ≥4000 copy/ml. Randomisation was performed with a random number code stratified by treatment centre and stage. The primary endpoint was failure-free survival（FFS).The calculated sample size was 169 per group, with an 80% power (one-sided α 0.05). Results: Between November 11, 2015 and August 4, 2020, 341 NPC patients were randomly assigned to receive either RT (n=172) or CCRT（n=169). After a median follow-up of 41 months, intention-to-treat analysis showed that 3-year FFS was 90.7% (95% CI 86.2–95.2) in the RT group, and 92.1% (95%CI 88.8–96.4) in the CCRT group, with a difference of -1.4% (upper limit of the one-sided 95% CI 4.5; p non-inferiority =0.00017). Similarly excellent FFS was found in the per-protocol analysis: 3year FFS for RT versus CCRT was 90.3% (95% CI 85.6–95.0) and 92.1% (95% CI 87.8–96.4), respectively, with a difference of -1.8% (upper limit of the one-sided 95% CI 4.3; p non-inferiority =0.00014). No differences were observed between groups in terms of overall survival, locoregional relapse and distant metastasis. Patients in the CCRT group developed significantly more grade 3-4 hematologic and nonhematologic adverse events such as vomiting (CCRT group 14.8% vs. RT group 1.2%), anorexia (29.9% vs. 4.8%), mucositis (18.9 % vs. 9.7%) and weight loss(4.7% vs. 0.6%). No patients died from treatment-related causes. Conclusions: Radiotherapy alone provides comparable disease control or survival and less toxicity compared to CCRT in the intermediate risk NPC. Clinical trial information: NCT02633202. RT group(%) CCRT group (%) P value Intention-to-treat population n = 172 n = 169 3-yr overall survival 98.7 99.4 0.178 3-yr distant metastasis-free survival 95.6 98.1 0.136 3-yr locoregional recurrence-free survival 94.4 93.9 0.975 Per-protocol population n = 165 n = 169 3-yr overall survival 98.7 99.4 0.159 3-yr distant metastasis-free survival 95.4 98.1 0.118 3-yr locoregional recurrence-free survival 94.2 93.9 0.890

Combined Hyperfractionated Radiotherapy and Concurrent Chemotherapy for Stage III-IV Nasopharyngel Carinoma

A Phase Iii Study of Late Course Accelerated Hyperfractionated Radiotherapy Versus Conventionally Fractionated Radiotherapy in Patients with Nasopharyngeal Carcinoma

Concurrent chemoradiotherapy followed by adjuvant chemotherapy for locally advanced nasopharyngeal carcinoma

1108OChemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: A randomized, open-label, phase III trial

Radiotherapy Combined with Chemotherapy in the Treatment of Patients with Advanced Nasopharyngeal Carcinoma

Concurrent chemoradiotherapy versus radiotherapy alone for T3-4N0-1M0 and T1-4N2-3M0 nasopharyngeal carcinoma after induction chemotherapy

IMRT Combined with Concurrent Chemotherapy Plus Adjuvant Chemotherapy Versus IMRT Combined with Concurrent Chemotherapy Alone in Patients with Nasopharyngeal Carcinoma

[Concomitant Chemo-Radiotherapy for Locoregionally Advanced Nasopharygeal Carcinoma].

Radiotherapy Alone Versus Concurrent Chemoradiotherapy in Intermediate Risk Nasopharyngeal Carcinoma: A Multicentre, Open-Label, Noninferiority, Randomised Phase III Trial.

Later course accelerated hyperfractionated radiotherapy combined with chemotherapy for advanced nasopharyngeal carcinoma

Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.

Preliminary Results of a Phase III Randomized Study Comparing Chemotherapy Neoadjuvantly or Concurrently with Radiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Clinical Study of Irradiation Combined with Late Course Chemotherapy in Nasopharyngeal Carcinoma

Radiotherapy Alone Vs Radiotherapy with Concurrent Chemoradiotherapy in Patients with Low-Risk Nasopharyngeal Carcinoma: Updated Results from a Multicenter, Open-Label, Non-Inferiority, Randomized Phase III Trial.

Efficacy of Conventional Radiotherapy and Late Course Accelerated Hyperfractionationated Radiotherapy for Nasopharyngeal Carcinoma

Mixed Photon and Carbon-Ion Beam Radiotherapy in the Management of Non-Metastatic Nasopharyngeal Carcinoma

Role of Chemoradiotherapy in Intermediate Prognosis Nasopharyngeal Carcinoma

Hypofractionated Radiotherapy compared with Conventionally Fractionated Radiotherapy to treat Initial Distant Metastases in Nasopharyngeal Carcinoma: A Multicenter, prospective, randomized, Phase II Trial

Five-year Efficacy Analysis of PF Chemotherapy Combined with Radiotherapy in Patients with Local-Advanced Nasopharyngeal Carcinoma

Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Treatment Outcomes of a Prospective, Multicentric Clinical Study